Baxter International is a global medical products and services company. Via its principal operating subsidiary, Baxter Healthcare Corporation, the company delivers products, which are sold in over 100 countries and are used by health-care professionals and their patients in the treatment of complex medical conditions, including haemophilia, immune disorders, kidney disease, cancer and trauma.
Baxter International posts Q1 profit, on strong sales
19th Apr 2012, 3:58 pm by Brad Lemaire
Drug and medical device maker () reported first-quarter profit grew three percent on Thursday amid strong demand for its hemophilia and immune disease treatments.
Net earnings climbed to $588 million, or $1.04 per share for the quarter ended March 31. This compares with $570 million, or 98 cents per share, last year.
Stripping out one-time items, the company earned $1.01 per share.
Revenue rose by three percent to $3.39 billion from $3.28 billion.
On average, analysts were forecasting profits of $1 per share, on revenue of $3.30 billion, according to Bloomberg.
The BioScience division reported sales growth of four percent to $1.5 billion, driven by strong demand for Advate used for the treatment of haemophilia.
Revenue from its Medical Products unit rose three percent to $1.9 billion, fuelled by strong growth in anesthesia products and injectable and nutritional therapies.
Quarterly results were also bolstered by Baxter’s $325 million acquisition of in February.
Synovis makes medical devices used procedures like soft tissue repair, obesity and vascular surgery, and hernia repair.
Gross margin slipped though to 50.6 percent from 51 percent.
In addition, Baxter raised the low end of its full-year profit forecast. It now expects earnings of between $4.49 to $4.57 per share. The company is also expecting revenue growth of two to three percent.
Analysts expect a profit of $4.54 per share and $14.19 billion in revenue, on average.
For the second-quarter, the company expects to make $1.10 to $1.12 per share, and said revenue will be unchanged to up as much as one percent.
Analysts expect Baxter to post earnings of $1.12 per share and $3.56 billion in revenue.
No investment advice
Proactive Investors North America Inc, trades as "Proactiveinvestors USA & Canada".
You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.
You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.
From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.
You understand that we may be providing advertising and/or marketing services to companies mentioned on the site. A full list of companies that are paying for services from us, or our affiliated companies in the UK and Australia can be viewed here
